We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Objective: To quantitate the separate impact of obesity and hyperlycemia on the incretin effect (i.e., the gain in β-cell function after oral glucose versus intravenous glucose). Research Design ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

1 In this article, we explore the impact of incretin-mimetic drugs on muscle health and what can be done to limit these severe side effects. Incretins are intestinal hormones secreted in response to ...

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...

Eli Lilly LLY-0.39%decrease; red down pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

Cardiorenal effects of SGLT2 and incretin agents SGLT2 inhibitors work directly on the kidney through the SGLT2 cotransporter to directly improve energy metabolism and function in the kidney.